Last updated: February 15, 2026
NDC 51672-2073 corresponds to Rociletinib, an investigational drug developed by Clovis Oncology targeting non-small cell lung cancer (NSCLC) with EGFR mutations. Given its developmental status, current market projections are speculative and depend on regulatory and commercial outcomes.
Current Status and Regulatory Outlook
As of 2023, Rociletinib has not received FDA approval. The drug was involved in clinical trials, but the sponsor discontinued development in 2018 due to safety concerns and unsatisfactory efficacy data. Without FDA approval, Rociletinib remains unavailable for commercial sale.
Key developments include:
- Clinical Trials: Completed Phase 2 and Phase 3 trials. Results showed limited efficacy and safety issues.
- Regulatory History: FDA rejection in 2016 citing safety concerns, leading to the cessation of development.
- Market Exit: Clovis Oncology suspended the development of Rociletinib in early 2018, citing commercial and scientific hurdles.
Market Landscape for EGFR-Inhibitors in NSCLC
The NSCLC EGFR inhibitor market is highly competitive, centered around approved drugs:
| Drug Name |
Approvals |
Sales 2022 (USD billions) |
Market Share (2022) |
Development Stage |
| Osimertinib (Tagrisso) |
FDA approved |
8.0 |
45% |
Established |
| Erlotinib (Tarceva) |
FDA approved |
1.2 |
7% |
Established |
| Afatinib (Gilotrif) |
FDA approved |
0.8 |
4% |
Established |
| Other |
-- |
— |
44% |
Includes pipeline candidates |
The market's leading player is AstraZeneca's Osimertinib, which commands a dominant position, making entry for new drugs challenging absent significant advantages.
Potential Market Entry Scenarios for Rociletinib
Scenario 1: Regulatory Approval
- Probability: Low, given historical data.
- Implications: If approved, the drug could target unmet needs in resistant NSCLC or specific patient subsets.
Scenario 2: Market Re-entry via Reformulation or New Data
- Requirements: Demonstrate improved safety and efficacy, possibly via new trials.
- Time horizon: 3-5 years for approval and market penetration.
Scenario 3: Strategic Licensing or Acquisition
- Buyout Target: Roche, Novartis, or smaller biotech firms interested in EGFR-targeted therapies.
- Price Range: $100 million to $500 million, based on prior clinical data and market potential.
Price Projections
If approved:
- The price of EGFR inhibitors averages around $10,000 to $15,000/month per patient (source: SSR Health, 2022).
- New entrants typically command a premium initially due to patent exclusivity.
Market penetration estimates:
| Year |
Patients (Global) |
Assumed Market Share |
Revenue (USD millions) |
Price per Patient/Year |
| Year 1 |
10,000 |
5% |
150 |
$15,000/month |
| Year 3 |
30,000 |
15% |
600 |
$15,000/month |
| Year 5 |
50,000 |
20% |
1,200 |
$15,000/month |
Pricing might decrease over time with generic competition or biosimilar entries.
Legal and Competitive Risks
- Patent landscape: Existing patents on comparable EGFR inhibitors may limit patentability.
- Market access: Gaining reimbursement approval demands robust clinical data.
- Regulatory hurdles: Safety issues historically raised by FDA could re-emerge, impacting approval timing and market access.
Summary
- Rociletinib remains in non-commercial use without FDA approval.
- Market entry prospects rely on overcoming safety and efficacy barriers.
- The current landscape favors well-established drugs like Osimertinib, demanding significant differentiation for new entrants.
- Price estimates for a successfully approved drug are $10,000–$15,000 per month, with potential annual revenues of $100 million+ if market penetration targets are achieved.
Key Takeaways
- Rociletinib's market potential hinges on overcoming historical safety concerns and gaining regulatory approval.
- The NSCLC EGFR inhibitor market is mature, dominated by few players, and challenging for new entrants.
- Price projections are aligned with existing EGFR inhibitors, with initial premium pricing possible.
- Market entry involves substantial risk, with possible licensing or acquisition strategies more realistic than standalone development.
- Competitive landscape and patent status heavily influence valuation and pricing strategies.
FAQs
1. Is Rociletinib currently available for prescription?
No, Rociletinib has not received FDA approval and is not commercially available.
2. What is the main obstacle for Rociletinib’s market entry?
FDA safety concerns and suboptimal efficacy data from clinical trials.
3. Which drugs dominate the NSCLC EGFR inhibitor market?
Osimertinib (Tagrisso) by AstraZeneca holds about 45% market share as of 2022.
4. What could be the typical price range for a new EGFR inhibitor?
$10,000 to $15,000 per month per patient.
5. What strategies could facilitate Rociletinib entering the market?
Gaining approval through additional trials addressing safety concerns, licensing, or strategic acquisition are options.
References
- SSR Health Data, 2022.
- FDA Drug Approvals and Discontinuations, 2016–2018.
- Market Share Data, EvaluatePharma, 2022.
- ClinicalTrials.gov listings for Rociletinib trials.
